MUSCONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H30O
Molecular Weight	238.4088
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1CCCCCCCCCCCCC(=O)C1

InChI

InChIKey=ALHUZKCOMYUFRB-OAHLLOKOSA-N

InChI=1S/C16H30O/c1-15-12-10-8-6-4-2-3-5-7-9-11-13-16(17)14-15/h15H,2-14H2,1H3/t15-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19763723 | https://www.ncbi.nlm.nih.gov/pubmed/15339420 | https://www.ncbi.nlm.nih.gov/pubmed/22978231

Muscone is the key flavor component of musk that is one of the most popular natural perfumes. Muscone is a promising agent for treating intervertebral disc degeneration through its anti-inflammatory effects. Musk distributing into the brain through blood brain barrier provides the basis for its effect in treating brain disorders. Muscone may be a small active molecule with neuroprotective properties, and that inhibition of apoptosis and Fas is an important mechanism of neuroprotection by muscone. These findings suggest a potential therapeutic role for muscone in the treatment of stroke. Muscone has a protective effect against ischemia-reperfusion injury in cardiac myocytes, indicating that muscone may potentially provide therapeutic benefit in ischemia-reperfusion injury by inhibiting cellular oxidative stress and apoptosis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Apoptosis 155 Target ID: WP254 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21856397	Inhibitor 8297
Oxidative Stress 160 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21856397	Inhibitor 8297
Fas signaling pathway 1 Target ID: GO:0036337 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22978231	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Intervertebral disc degradation 4 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19763723	Primary	Preclinical	Unknown Approved Use Unknown
Myocardial infarction 121 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21856397	Primary	Basic research	Unknown Approved Use Unknown
Stroke 144 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22978231	Primary	Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Induction of cytochrome P450 3A by Shexiang Baoxin Pill and its main components.	2012 Jan 25	22178124

Patents

Sample Use Guides

In Vivo Use Guide

150 mg/kg for 3 days

Route of Administration: Intraperitoneal

In Vitro Use Guide

In end-plate chondrocytes, exogenous IL-1b resulted in an increase of endogenous IL-1b, TNF-a, and COX-2 mRNA expression, but treatment with 25 uM/L muscone reduced the three cytokines induced by exogenous IL-1b. In end-plate chondrocytes, nitrite levels were induced by IL-1b. The response was attenuated by muscone in a dose-dependent manner, especially by 25 uM/L muscone.

Name

Type

Language

MUSCONE

Official Name

English

MUSCONE [INCI]

Common Name

English

(-)-3-METHYLCYCLOPENTADECANONE

Systematic Name

English

MUSCONE [MI]

Common Name

English

CYCLOPENTADECANONE, 3-METHYL-, (3R)-

Systematic Name

English

(-)-(3R)-3-METHYLCYCLOPENTADECANONE

Systematic Name

English

Code System Code Type Description

FDA UNII

UPS3C6CV36